Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Ivonescimab
Advertisement
HUTCHMED and GSK Partner on KRAS-EGFR Cancer Therapy
Hong Kong, Shanghai & Florham Park, New Jersey, USA, September 3, 2026 HUTCHMED (China) Limited and GSK have entered...
Akeso Reports 2026 Growth, Advances Global Drug Pipeline
HONG KONG, Aug 27, 2026 Akeso, Inc. announced its 2026 interim results, reporting record commercial drug sales while advancing...
Summit Advances Ivonescimab in Global HARMONi Trial
August 25, 2026 | Miami, Florida, USA Summit Therapeutics Inc. has announced the publication of primary analysis results from...
Akeso Advances AK157D1 B7-H3 ADC Into Phase I
Hong Kong, August 21, 2026 Akeso, Inc. has announced that its investigational B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received...
Advertisements
Obsidian Therapeutics Enrolls First Patient in Registration-Enabling Agni-01 Melanoma Trial
CAMBRIDGE, Mass., August 5, 2026 Obsidian Therapeutics announced the enrollment of the first patient in the registration-enabling cohort of...
Summit Therapeutics Launches Global Phase 3 Ivonescimab Trial in Bladder Cancer
MIAMI, August 5, 2026 Summit Therapeutics announced the launch of the Phase II/III HARMONi-GU1 study, the company’s first global...
Akeso Doses First Patient in HER3 ADC Lung Cancer Trial
Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...
Akeso Starts Phase II Trial of AK146D1 for Advanced NSCLC
HONG KONG, July 20, 2026 Akeso, Inc. has announced a significant milestone in its oncology pipeline with the first...
Advertisement
